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BACKGROUND
No systemic therapies have been approved for the treatment of advanced cutaneous 
squamous-cell carcinoma. This cancer may be responsive to immune therapy, because 
the mutation burden of the tumor is high and the disease risk is strongly associated 
with immunosuppression. In the dose-escalation portion of the phase 1 study of 
cemiplimab, a deep and durable response was observed in a patient with metastatic 
cutaneous squamous-cell carcinoma.
METHODS
We report the results of the phase 1 study of cemiplimab for expansion cohorts of 
patients with locally advanced or metastatic cutaneous squamous-cell carcinoma, 
as well as the results of the pivotal phase 2 study for a cohort of patients with 
metastatic disease (metastatic-disease cohort). In both studies, the patients received 
an intravenous dose of cemiplimab (3 mg per kilogram of body weight) every 2 weeks 
and were assessed for a response every 8 weeks. In the phase 2 study, the primary 
end point was the response rate, as assessed by independent central review.
RESULTS
In the expansion cohorts of the phase 1 study, a response to cemiplimab was ob-
served in 13 of 26 patients (50%; 95% confidence interval [CI], 30 to 70). In the 
metastatic-disease cohort of the phase 2 study, a response was observed in 28 of 
59 patients (47%; 95% CI, 34 to 61). The median follow-up was 7.9 months in the 
metastatic-disease cohort of the phase 2 study. Among the 28 patients who had a 
response, the duration of response exceeded 6 months in 57%, and 82% continued 
to have a response and to receive cemiplimab at the time of data cutoff. Adverse 
events that occurred in at least 15% of the patients in the metastatic-disease cohort 
of the phase 2 study were diarrhea, fatigue, nausea, constipation, and rash; 7% of 
the patients discontinued treatment because of an adverse event.
CONCLUSIONS
Among patients with advanced cutaneous squamous-cell carcinoma, cemiplimab 
induced a response in approximately half the patients and was associated with 
adverse events that usually occur with immune checkpoint inhibitors. (Funded by 
Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov numbers, NCT02383212 
and NCT02760498.)
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Cutaneous squamous-cell carcinoma is the second most common skin cancer; only basal-cell carcinoma has a higher in-
cidence.1,2 Risk factors for cutaneous squamous-
cell carcinoma include chronic sun exposure, ad-
vanced age, skin that is sensitive to ultraviolet 
radiation, and immunosuppression.3 In more than 
95% of patients, the cancer is cured with surgery.4 
In a small percentage of patients, the tumor 
reaches an incurable state because it becomes 
metastatic or has locally advanced progression and 
is no longer amenable to surgery or radiation 
therapy. Advanced cutaneous squamous-cell car-
cinoma is a condition that encompasses these two 
incurable situations, and patients with this con-
dition are considered for palliative systemic ther-
apy, which can be administered as part of routine 
clinical practice.5-7 In 2012, an estimated 3900 to 
8700 people in the United States died from cuta-
neous squamous-cell carcinoma.8
Cutaneous squamous-cell carcinoma has the 
clinical and molecular hallmarks of a tumor that 
is likely to be responsive to systemic immune 
therapy: the mutation burden of the tumor is high, 
and the disease risk is increased among patients 
with immunosuppression.9-11 Patients who have 
undergone solid-organ transplantation and are 
receiving immunosuppressive therapy have a risk 
of cutaneous squamous-cell carcinoma that is 65 
to 250 times as high as the risk in the general 
population,9 which suggests that immune surveil-
lance is critical for preventing cutaneous squa-
mous-cell carcinoma in immunocompetent peo-
ple. Most patients with cutaneous squamous-cell 
carcinoma have hypermutated tumors because 
of chronic skin damage from ultraviolet light,10,11 
and patients who have tumors with a high muta-
tion burden are more likely to have a response to 
immune therapy with a checkpoint inhibitor, pos-
sibly because the tumors have increased neoantigen 
expression.12-14
Cemiplimab is a high-affinity, highly potent 
human monoclonal antibody directed against pro-
grammed death 1 (PD-1).15 In the dose-escalation 
portion of the phase 1 study of cemiplimab, a deep 
and durable response was observed in a patient 
with advanced cutaneous squamous-cell carcino-
ma.16 We report the results of the phase 1 study 
for expansion cohorts of patients with locally 
advanced or metastatic cutaneous squamous-cell 
carcinoma, as well as the results of the primary 
analysis of the pivotal phase 2 study for a cohort 
of patients with metastatic disease (metastatic-
disease cohort). The primary objective of the phase 
2 study was to establish the clinical benefit of ce-
miplimab, as measured by an objective response 
rate. A key secondary objective was to assess the 
duration of response to cemiplimab within the 
limits of study follow-up.
Me thods
Patients
The expansion cohorts of the phase 1 study in-
volved adult patients who had advanced (locally 
advanced or metastatic) cutaneous squamous-cell 
carcinoma. Patients who had locally advanced dis-
ease were eligible for inclusion in the study if they 
were not candidates for surgery for one or both 
of the following reasons: they had disease recur-
rence after two or more surgical procedures and 
the treating clinicians expected that curative re-
section would be unlikely, or the treating clinicians 
anticipated that surgery would result in substan-
tial complications or deformity. The phase 2 study 
was designed to involve adult patients who had 
metastatic cutaneous squamous-cell carcinoma 
with distant or regional metastasis or both 
(group 1), as well as adult patients who had lo-
cally advanced cutaneous squamous-cell carci-
noma (group 2). The time point for the primary 
analysis was reached for the metastatic-disease 
cohort. Thus, we report the results of the phase 
1 study for the expansion cohorts, as well as the 
results of the primary analysis of the phase 2 
study for the metastatic-disease cohort. Results 
of the phase 2 study for the locally advanced–
disease cohort are not included in this article, 
because the data are interim and the time point 
for the primary analysis (according to the statis-
tical analysis plan) has not yet been reached.
For both studies, key eligibility criteria were 
an Eastern Cooperative Oncology Group perfor-
mance status score of 0 or 1 (on a 5-point scale, 
with higher scores indicating greater disability), 
adequate organ function, and the presence of at 
least one lesion that could be measured according 
to Response Evaluation Criteria in Solid Tumors 
(RECIST), version 1.1.17 Patients were excluded if 
they had ongoing or recent (within 5 years) auto-
immune disease that was treated with systemic 
immunosuppressive therapy or if they had previ-
ously received treatment with anti–PD-1 or anti–
programmed death ligand 1 therapy, had un-
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dergone solid-organ transplantation, or had 
concurrent cancer, unless the disease was indo-
lent or was not considered to be life-threatening 
(e.g., basal-cell carcinoma). Patients who had he-
matologic cancer (e.g., chronic lymphocytic leu-
kemia) were excluded from the phase 2 study. For 
details about the inclusion and exclusion criteria, 
see the study protocols, available with the full text 
of this article at NEJM.org.
Study Design
The phase 1 study was an open-label, multicenter 
study of cemiplimab that involved patients with 
advanced solid-tumor cancers. The primary end 
point was the safety and side-effect profile of 
cemiplimab. The phase 2 study was a nonran-
domized, global, pivotal study of cemiplimab in-
volving patients with advanced cutaneous squa-
mous-cell carcinoma. The primary end point was 
the response rate, as assessed by independent 
central review. For both studies, secondary end 
points included the duration of response, pro-
gression-free survival, overall survival, and toxic 
effects. An additional analysis was performed to 
evaluate the rate of durable disease control, which 
was defined as the proportion of patients who 
Characteristic
Expansion Cohorts 
of the Phase 1 Study 
(N = 26)
Metastatic-Disease Cohort 
of the Phase 2 Study 
(N = 59)
Age
Median (range) — yr 73 (55–88) 71 (38–93)
≥65 yr — no. (%) 21 (81) 43 (73)
Male sex — no. (%) 21 (81) 54 (92)
ECOG performance status score — no. (%)†
0 10 (38) 23 (39)
1 16 (62) 36 (61)
Primary site of cutaneous squamous‑cell carcinoma — no. (%)
Head or neck 18 (69) 38 (64)
Arm or leg 5 (19) 12 (20)
Trunk 2 (8) 9 (15)
Penis 1 (4) 0
Previous systemic therapy for cutaneous squamous‑cell  
carcinoma — no. of patients (%)‡
No regimens 8 (31) 26 (44)
Any regimen 15 (58) 33 (56)
1 regimen 15 (58) 22 (37)
≥2 regimens 0 11 (19)
Previous radiotherapy for cutaneous squamous‑cell  
carcinoma — no. (%)
20 (77) 50 (85)
Extent of cutaneous squamous‑cell carcinoma — no. (%)
Distant metastasis 8 (31) 45 (76)
Regional metastasis only 8 (31) 14 (24)
Locally advanced progression only 10 (38) 0
*  The expansion cohorts of the phase 1 study involved patients with metastatic or locally advanced cutaneous squamous‑
cell carcinoma. The metastatic‑disease cohort of the phase 2 study involved patients with metastatic cutaneous squa‑
mous‑cell carcinoma.
†  Eastern Cooperative Oncology Group (ECOG) performance status scores are measured on a 5‑point scale, with higher 
scores indicating greater disability.
‡  In the phase 1 cohorts, previous systemic therapies were unknown for 3 patients. In the phase 2 cohort, 14 patients 
had received previous systemic therapy for cutaneous squamous‑cell carcinoma with palliative intent.
Table 1. Baseline Characteristics of the Patients.*
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did not have progressive disease for at least 105 
days. The treatment regimen was an intravenous 
dose of cemiplimab (3 mg per kilogram of body 
weight, administered over a period of 30 minutes) 
every 2 weeks. The duration of treatment was up 
to 48 weeks in the phase 1 study and up to 96 
weeks in the phase 2 study or until the patient 
had unacceptable toxic effects or had confirmed 
disease progression.
Study Oversight
For both studies, the protocols and all amend-
ments were approved by the institutional review 
board at each participating study site; the proto-
cols, statistical analysis plans, and amendments 
are available at NEJM.org. The studies were con-
ducted in accordance with the principles of the 
Declaration of Helsinki and the International 
Conference on Harmonisation Good Clinical Prac-
tice guidelines. The patients provided written in-
formed consent before enrollment.
The studies were sponsored by Regeneron 
Pharmaceuticals and Sanofi. They were designed 
by employees of Regeneron Pharmaceuticals in 
collaboration with the authors. The phase 2 study 
was overseen by a steering committee. For each 
study, efficacy results were reviewed by an inde-
pendent central response-assessment committee. 
The data were collected by investigators, analyzed 
by statisticians employed by the sponsors, and 
interpreted by the authors, including employees 
of the sponsors. The authors had unrestricted ac-
cess to the data, were responsible for all content 
and editorial decisions, and received no honoraria 
related to the development of the manuscript. 
The authors, in collaboration with the sponsors, 
made the decision to submit the manuscript for 
publication when the primary analysis of the phase 
2 study was completed, in accordance with the 
statistical analysis plan.
The first draft of the manuscript was prepared 
by a medical writer, who was paid by the sponsors; 
the draft was based on comments that were pro-
vided by the authors on the manuscript outline, 
which was also prepared by the medical writer. 
Thereafter, the first draft was critically reviewed 
and revised by the authors. The sponsors provided 
comments on an early draft. The authors agreed 
to maintain confidentiality of the data until pub-
lication and vouch for the accuracy and complete-
Outcome
Expansion Cohorts 
of the Phase 1 Study 
(N = 26)
Metastatic-Disease Cohort 
of the Phase 2 Study 
(N = 59)
Best overall response — no. (%)†
Complete response 0 4 (7)
Partial response 13 (50) 24 (41)
Stable disease 6 (23) 9 (15)
Progressive disease 3 (12) 11 (19)
Could not be evaluated‡ 3 (12) 7 (12)
Nontarget lesions only§ 1 (4) 4 (7)
Objective response — % (95% CI) 50 (30–70) 47 (34–61)
Durable disease control — % (95% CI) 65 (44–83) 61 (47–74)
Median observed time to response (range) — mo¶ 2.3 (1.7–7.3) 1.9 (1.7–6.0)
*  The expansion cohorts of the phase 1 study involved patients with metastatic or locally advanced cutaneous squamous‑
cell carcinoma. The metastatic‑disease cohort of the phase 2 study involved patients with metastatic cutaneous squa‑
mous‑cell carcinoma.
†  To determine the tumor response, results of whole‑body imaging were evaluated according to Response Evaluation 
Criteria in Solid Tumors (RECIST), version 1.1. In the phase 2 study, digital medical photographs were evaluated ac‑
cording to protocol‑specified composite response criteria.
‡  The data include patients who did not undergo imaging studies after the initiation of therapy or had imaging studies 
that could not be evaluated by independent central review.
§  The data include patients who had nontarget lesions only (i.e., lesions that could not be measured according to RECIST, 
version 1.1) and did not have disappearance of all lesions or unequivocal progression.
¶  The data are from patients who had a confirmed complete or partial response.
Table 2. Tumor Response to Cemiplimab, as Assessed by Independent Central Review.*
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ness of the data and the fidelity of the studies to 
the protocols.
Assessments
In both studies, the patients were assessed for a 
response to cemiplimab every 8 weeks by means of 
imaging studies. Results of whole-body imaging 
were evaluated according to RECIST, version 1.1.17 
In the phase 2 study, digital medical photographs 
of the skin were evaluated according to protocol-
specified composite response criteria. Confirma-
tory imaging studies were obtained no less than 
Figure 1. Effect of Cemiplimab in Patients with Advanced Cutaneous Squamous-Cell Carcinoma.
Panel A shows a 62‑year‑old patient at baseline and after 6 weeks of treatment with cemiplimab. Panel B shows an 
83‑year‑old patient, who had undergone multiple surgeries for cutaneous squamous‑cell carcinoma, at baseline and 
after 8 weeks of treatment with cemiplimab.
B
A
Patient in Phase 2 Study
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4 weeks after the initial documentation of a re-
sponse. Patients who received at least one dose 
of cemiplimab were assessed for toxic effects 
during the treatment phase; the assessment in-
cluded adverse-event reporting, laboratory tests, 
electrocardiograms, and measurement of vital 
signs. The severity of adverse events was graded 
according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events, ver-
sion 4.03.
Statistical Analysis
The results are presented in accordance with the 
intention-to-treat principle. The data cutoff points 
were October 2, 2017, for the expansion cohorts 
of the phase 1 study and October 27, 2017, for the 
metastatic-disease cohort of the phase 2 study. 
For the phase 1 cohorts, the analysis did not in-
clude formal hypothesis testing. For the phase 2 
cohort, the primary analysis was based on a sin-
gle-stage exact binomial design, with a null hy-
pothesis that the response rate would be 15% or 
less. We calculated that a sample of 50 patients 
would give the phase 2 study 85% power to re-
ject the null hypothesis if the true response rate 
was at least 34%. In accordance with the statisti-
cal analysis plan for the phase 2 study, the pri-
mary analysis was conducted 6 months after the 
first dose of cemiplimab had been administered 
in the last patient to be enrolled.
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R esult s
Expansion Cohorts of the Phase 1 Study
From March 2016 through January 2017, a total 
of 26 patients with advanced cutaneous squa-
mous-cell carcinoma were enrolled in expansion 
cohorts of the phase 1 study and were treated 
with cemiplimab. The median age was 73 years 
(range, 55 to 88). With respect to previous treat-
ments for cutaneous squamous-cell carcinoma, 
15 patients (58%) had received previous systemic 
therapy and 20 (77%) had received previous radio-
therapy. Data on baseline characteristics, dispo-
sition, and exposure to cemiplimab are summa-
rized in Table 1, and in Tables S1 and S2 in the 
Supplementary Appendix, available at NEJM.org.
The median follow-up was 11.0 months (range, 
1.1 to 17.0). The most common adverse events of 
any grade were fatigue (occurring in 27% of the 
patients), as well as constipation, decreased appe-
tite, diarrhea, hypercalcemia, hypophosphatemia, 
nausea, and urinary tract infection (each occurring 
in 15% of the patients). There were five deaths: 
three were due to disease progression, one was due 
to an unknown cause in a patient who had dis-
continued treatment because of disease progres-
sion and was subsequently lost to follow-up, and 
one was due to an adverse event. Details about 
the fatal adverse event are provided in Table S3 
in the Supplementary Appendix. Adverse events 
that were assessed by investigators to be related 
to the treatment are shown in Table S4 in the 
Supplementary Appendix.
The response rate, as assessed by independent 
central review, was 50% (95% confidence interval 
[CI], 30 to 70) (Table 2). The rate of durable disease 
control was 65% (95% CI, 44 to 83). The median 
observed time to response was 2.3 months (range, 
1.7 to 7.3). The duration of response exceeded 
6 months in 7 of the 13 patients who had a re-
sponse (54%). Figure 1A shows a patient who had 
a rapid tumor reduction after 6 weeks of treatment 
with cemiplimab.
Metastatic-Disease Cohort  
of the Phase 2 Study
Patient Characteristics
From May 2016 through April 2017, a total of 59 
patients with metastatic cutaneous squamous-cell 
Figure 2 (facing page). Tumor Response to Cemiplimab 
among Patients in the Phase 2 Study Who Had  
Metastatic Cutaneous Squamous-Cell Carcinoma.
Panel A shows the best percentage change from  
baseline in the sum of the diameters of the target  
lesions for each of the 45 patients in the metastatic‑
disease cohort of the phase 2 study who underwent 
imaging studies after the initiation of therapy, as well 
as the best response for each patient. The results of 
imaging studies were assessed by independent central 
review. Target lesions were lesions that could be mea‑
sured according to Response Evaluation Criteria in 
Solid Tumors (RECIST), version 1.1; patients could 
have up to two target lesions per organ and five total 
target lesions. Nontarget lesions were lesions that 
could not be measured according to RECIST, version 
1.1; patients with nontarget lesions only were consid‑
ered to have a noncomplete response or nonprogres‑
sive disease, unless there was disappearance of all  
lesions or unequivocal progression. Measurements 
that were obtained after disease progression were ex‑
cluded. A partial response was defined as a decrease 
in the sum of the target‑lesion diameters of at least 
30%, and progressive disease was defined as an in‑
crease in the sum of the target‑lesion diameters of at 
least 20%. Three patients who had a decrease in the 
sum of the target‑lesion diameters of at least 30% 
were classified as having progressive disease (red  
bars below baseline) because they had a new lesion  
or progression of a nontarget lesion. One patient had 
stable disease according to RECIST, version 1.1, but 
could not be evaluated overall (yellow bar) because 
the digital medical photographs could not be evaluat‑
ed. The graph does not show data for the following 
patients (although they were included in the primary 
analysis): 3 patients who had new lesions or progres‑
sion of nontarget lesions but had target lesions that 
could not be evaluated after the initiation of therapy,  
1 patient who had a complete response but had non‑
target lesions only at baseline, 4 patients who had 
nontarget lesions only, and 6 patients who had a tar‑
get lesion that could not be evaluated after the initia‑
tion of therapy. Panel B shows the time to response 
and the duration of response for the 28 patients in  
the metastatic‑disease cohort of the phase 2 study 
who had a response. Of the 28 patients, 23 continued 
to have a response at the time of data cutoff, 3 had 
progressive disease, 1 had surgical removal of the  
responsive target lesion and thus had censored data 
after surgery (top line), and 1 had a confirmed com‑
plete response but had censored data after being lost 
to follow‑up (second line from the top). One of the  
23 patients who continued to have a response  
(14th line from top) had nontarget lesions only  
and was deemed by independent central review to 
have a complete response after the lesions disap‑
peared.
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carcinoma were enrolled in the metastatic-disease 
cohort of the phase 2 study and were treated with 
cemiplimab. The median age was 71 years (range, 
38 to 93). With respect to previous treatments for 
cutaneous squamous-cell carcinoma, 33 patients 
(56%) had received previous systemic therapy 
and 50 (85%) had received previous radiotherapy 
(Table 1). Data on disposition and exposure to 
cemiplimab are shown in Tables S5 and S6 in 
the Supplementary Appendix. The median follow-
up was 7.9 months (range, 1.1 to 15.6).
Clinical Efficacy
The response rate, as assessed by independent 
central review, was 47% (95% CI, 34 to 61), and 
the rate of durable disease control was 61% (95% 
CI, 47 to 74). A partial response was observed in 
24 patients and a complete response in 4 patients 
(Table 2). Characteristics of the tumor responses 
are shown in Figure 2, and in Figure S1 in the 
Supplementary Appendix.
The median observed time to response was 
1.9 months (range, 1.7 to 6.0) (Table 2). The me-
dian duration of response had not been reached 
at the time of this analysis. However, the dura-
tion of response exceeded 6 months in 16 of the 
28 patients who had a response (57%). Among the 
28 patients with confirmed responses, 3 had sub-
sequent disease progression and data on the dura-
tion of response were censored for 2 (Fig. 2B). At 
the time of data cutoff, 23 of the 28 patients who 
had a response (82%) continued to have a response 
and to receive cemiplimab.
According to independent central review, nei-
ther the median progression-free survival nor 
the median overall survival had been reached at 
the time of data cutoff. The estimated probabil-
ity of progression-free survival at 12 months was 
53% (95% CI, 37 to 66) (Fig. 3), and the estimated 
probability of overall survival at 12 months was 
81% (95% CI, 68 to 89) (Fig. S2 in the Supplemen-
tary Appendix). Figure 1B shows the effect of 
cemiplimab on the natural course of advanced 
cutaneous squamous-cell carcinoma in a patient 
with metastatic disease and an externally visible 
lesion. (For additional examples, see Fig. S3 in 
the Supplementary Appendix.)
In subgroup analyses, similar efficacy was 
observed in patients with regional metastatic dis-
ease and in those with distant metastatic disease. 
A response was observed in 22 of 45 patients with 
distant metastasis (49%; 95% CI, 34 to 64) and in 
6 of 14 patients with regional metastasis (43%; 
95% CI, 18 to 71).
Adverse Events
The most common adverse events were diarrhea 
(occurring in 27% of the patients), fatigue (24%), 
nausea (17%), constipation (15%), and rash (15%) 
(Table 3, and Table S7 in the Supplementary Ap-
pendix). Four patients (7%) discontinued treatment 
because of an adverse event. Adverse events of 
grade 3 or higher that occurred in more than one 
patient were cellulitis, pneumonitis, hypercalce-
mia, pleural effusion, and death.
Overall, there were 11 deaths: 8 were due to 
disease progression, and 3 were due to adverse 
events. A 93-year-old man presented on study 
day 35 with fever and cough with purulent sputum, 
and he died from complications of pneumonia on 
day 38. A 72-year-old man died in his sleep on 
study day 41. A 90-year-old man who had disease 
progression (as assessed by independent central 
review) on study day 57 had a duodenal ulcer and 
esophagitis that resolved on day 64; the patient 
subsequently had hypercalcemia and deep-vein 
thrombosis and died on day 92. No autopsies were 
performed on these three patients. Adverse events 
that were assessed by investigators to be related 
to the treatment are shown in Table S8 in the 
Supplementary Appendix.
Figure 3. Kaplan–Meier Curves for the Probability of Progression-free 
 Survival among Patients in the Phase 2 Study Who Had Metastatic 
 Cutaneous Squamous-Cell Carcinoma.
In the metastatic‑disease cohort of the phase 2 study, the median progression‑
free survival had not been reached at the time of data cutoff. The estimated 
probability of progression‑free survival from baseline through 12 months 
was 53% (95% CI, 37 to 66), as assessed by independent central review.
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Discussion
Advanced cutaneous squamous-cell carcinoma is 
a life-threatening condition for which no systemic 
therapies have been approved. The study of ce-
miplimab for the treatment of advanced cutaneous 
squamous-cell carcinoma was underpinned by the 
recognition that a high mutation burden may ren-
der these tumors sensitive to effector T cells in 
the context of immune checkpoint blockade.18 In 
addition, the dramatically increased risk of cuta-
neous squamous-cell carcinoma among people 
with immunosuppression pointed to an important 
role for immune surveillance for this cancer. In 
the dose-escalation portion of the phase 1 study 
of cemiplimab, an objective response was observed 
in a patient with metastatic cutaneous squamous-
cell carcinoma.16 We report results showing ro-
bust efficacy of cemiplimab in the phase 1 study 
in expansion cohorts of patients with advanced 
cutaneous squamous-cell carcinoma, as well as 
in the phase 2 study in a cohort of patients with 
metastatic disease. The response rates were con-
sistent in the phase 1 cohorts and the phase 2 
cohort (50% and 47%, respectively), as were the 
characteristics of the tumor responses.
Cemiplimab had similar efficacy for the treat-
ment of metastatic and locally advanced cutaneous 
squamous-cell carcinoma. After integrating the 
results for the 75 patients who had metastatic 
disease in the two studies (the 59 patients in the 
metastatic-disease cohort of the phase 2 study 
plus the 16 patients in the phase 1 study who met 
the criteria for metastatic disease that were used 
in the phase 2 study), the response rate was 47% 
(95% CI, 35 to 59) (Table S9 in the Supplemen-
tary Appendix). Of the 10 patients in the expan-
sion cohorts who met the criteria for locally ad-
vanced disease that were used in the phase 2 study 
(i.e., no regional or distant metastasis), 6 had an 
objective response (Table S10 in the Supplemen-
tary Appendix). These results indicate that ad-
vanced cutaneous squamous-cell carcinoma tu-
mors, whether metastatic or locally advanced, 
are responsive to cemiplimab. The phase 2 study 
of cemiplimab for locally advanced cutaneous 
squamous-cell carcinoma is ongoing.
Most adverse events that were assessed by inves-
tigators to be related to the treatment were grade 
1 or 2 events, and 8% and 7% of the patients in 
the phase 1 cohorts and the phase 2 cohort, re-
spectively, discontinued treatment because of ad-
verse events. Despite the advanced age of the pa-
tients, no new safety signals were reported in these 
cohorts.19-21
Our results show the efficacy of cemiplimab 
for the treatment of cutaneous squamous-cell 
carcinoma in immunocompetent patients. We did 
not enroll immunocompromised patients, and 
thus we cannot comment on the efficacy of 
cemiplimab among such patients.
Our results are consistent with an emerging 
theme regarding the high efficacy of immune 
Event
Metastatic-Disease Cohort 
of the Phase 2 Study 
(N = 59)
Any Grade Grade ≥3
no. of patients (%)
Any 59 (100) 25 (42)
Serious 21 (36) 17 (29)
Led to discontinuation of treatment 4 (7) 3 (5)
Associated with an outcome of death 3 (5) 3 (5)
Occurred in ≥5 patients
Diarrhea 16 (27) 1 (2)
Fatigue 14 (24) 1 (2)
Nausea 10 (17) 0
Constipation 9 (15) 1 (2)
Rash 9 (15) 0
Cough 8 (14) 0
Decreased appetite 8 (14) 0
Pruritus 8 (14) 0
Headache 8 (14) 0
Dry skin 6 (10) 0
Maculopapular rash 6 (10) 0
Vomiting 6 (10) 0
Anemia 5 (8) 1 (2)
Hypothyroidism 5 (8) 0
Increased alanine aminotransferase 5 (8) 0
Pneumonitis 5 (8) 2 (3)
*  Events are listed as indicated on the case‑report form. Although rash and 
maculopapular rash may reflect the same condition, they were listed as two 
distinct events for the safety report of the phase 2 study. Adverse events were 
coded according to the Preferred Terms of the Medical Dictionary for Regula­
tory Activities, version 20.0. The severity of adverse events was graded accord‑
ing to the National Cancer Institute Common Terminology Criteria for Adverse 
Events, version 4.03. A complete list of adverse events that occurred in the 
metastatic‑disease cohort of the phase 2 study is provided in Table S7 in the 
Supplementary Appendix.
Table 3. Adverse Events.*
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checkpoint blockade for the treatment of hyper-
mutated cancers, since the mutation burden of 
cutaneous squamous-cell carcinoma is similar to 
that reported for advanced solid tumors with mi-
crosatellite instability.10,11,14,22 A pivotal phase 2 
study of cemiplimab for the treatment of advanced 
basal-cell carcinoma in immunocompetent pa-
tients is in progress (ClinicalTrials.gov number, 
NCT03132636).
In conclusion, among patients with advanced 
cutaneous squamous-cell carcinoma, cemiplimab 
induced a response in approximately half the pa-
tients and was associated with adverse events 
that are similar to those seen with other PD-1 
inhibitors.
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